Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.

Fable Zustovich, Giuseppe Lombardi, Davide Pastorelli, Patrizia Farina, Massimo Dal Bianco, Luca De Zorzi, Maurizia Dalla Palma, Ornella Nicoletto, Vittorina Zagonel
{"title":"Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.","authors":"Fable Zustovich,&nbsp;Giuseppe Lombardi,&nbsp;Davide Pastorelli,&nbsp;Patrizia Farina,&nbsp;Massimo Dal Bianco,&nbsp;Luca De Zorzi,&nbsp;Maurizia Dalla Palma,&nbsp;Ornella Nicoletto,&nbsp;Vittorina Zagonel","doi":"10.2147/OAJU.S7230","DOIUrl":null,"url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC. </p>","PeriodicalId":19572,"journal":{"name":"Open Access Journal of Urology","volume":"3 ","pages":"69-82"},"PeriodicalIF":0.0000,"publicationDate":"2011-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/OAJU.S7230","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Journal of Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OAJU.S7230","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

Abstract

Renal cell carcinoma (RCC) is a common malignancy worldwide with approximately 95,000 new cases per year and ranks as the sixth cause of cancer deaths. Until recently, the slightly active and very toxic cytokines were available for patients with advanced RCC. Advances have been made in understanding the molecular biology of renal cancer. The introduction of targeted agents has led to promising possibilities for treating these highly vascularized tumors. Angiogenesis inhibition is likely to represent the main potential therapeutic target. Sorafenib is an oral multikinase inhibitor with activity against tyrosine kinase receptors that are responsible for blood vessel development and has shown to be active in treating advanced RCC. In this review, we summarize the pharmacology, mode of action, pharmacokinetics, and safety of sorafenib use in therapy for advanced RCC.

Abstract Image

Abstract Image

Abstract Image

索拉非尼治疗肾细胞癌的临床经验及关键评价。
肾细胞癌(RCC)是世界范围内常见的恶性肿瘤,每年约有95,000例新病例,是癌症死亡的第六大原因。直到最近,轻度活性和毒性很强的细胞因子可用于晚期肾细胞癌患者。在了解肾癌的分子生物学方面取得了进展。靶向药物的引入为治疗这些高度血管化的肿瘤带来了希望。血管生成抑制可能是主要的潜在治疗靶点。索拉非尼是一种口服多激酶抑制剂,具有对抗酪氨酸激酶受体的活性,酪氨酸激酶受体负责血管发育,并已显示出治疗晚期RCC的活性。在这篇综述中,我们总结了索拉非尼在晚期肾癌治疗中的药理学、作用方式、药代动力学和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信